Skip to main content
OpenTrials
Completed

NCT Number: NCT05754814

SUper-Resolution Ultrasound Imaging of Erythrocytes (SURE) in Normal and Malignant Lymph Nodes

The goal of this observational study is to visualize the small vessels in normal and cancerous lymph nodes on the neck with a new ultrasound technique.

The main questions it aims to answer are:

* Is it possible to visualize the network of the smallest vessels in lymph nodes on the neck? * Is it possible to distinguish between healthy and cancerous lymph nodes using different parameters?

The participants will have 1 lymph nodes ultrasound scanned with a standard ultrasound technique and the new technique.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Super-resolution ultrasound using erythrocytes (SURE) is a new ultrasound technique for visualizing the very small blood vessels in the body. The technique uses tracking of the blood's red blood cells (erythrocytes) to achieve a higher resolution of the blood vessels' shape, structure, and blood flow. The technique makes it possible to create images with much higher resolution than normal ultrasound, which means that even very small blood vessels can be imaged and measured.

In many diseases, the small blood vessels change their function or structure. One of the major disease groups where SURE has significant potential is cancer. In cancerous nodes, the small blood vessels change: they become twisted, irregular, and function poorly. If changes in the small vessels can be detected at an early stage using SURE, it can lead to quicker diagnoses and better evaluations of the effectiveness of treatment.

In this study, the investigators aim to demonstrate the practical feasibility of SURE imaging in human lymph nodes and investigate the clinical relevance of SURE imaging in the diagnosis of malignant lymph nodes by comparing lymph nodes from healthy participants with lymph nodes from participants with head and neck cancer metastases or lymphoma.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be 18 years or older, at the time of signing the informed consent
  • Participants who can lie still for 1 minute
  • Capable of giving signed informed consent

Inclusion criteria

for healthy participants:

  • Participants who are overtly healthy as determined by medical history
  • Participants who have a superficial lymph node laterally on the neck with a normal appearance on standard B-mode ultrasound available for SURE imaging

Inclusion criteria

for participants with head and neck cancer or lymphoma:

  • Participants who, besides their untreated head and neck cancer or lymphoma, are overtly healthy as determined by medical evaluation and medical history
  • Participants with lymphoma or head and neck cancer and lymph node metastasis verified by a biopsy or surgical excision.
  • Participants who have superficial lymph nodes laterally on the neck

Exclusion criteria

  • Pregnancy
  • Dementia
  • Physique making ultrasound scanning difficult
  • Ongoing or recent (within the last 4 weeks) infectious disease (bacterial, viral, fungal, or protozoal) which may give rise to reactive lymph nodes
  • Diseases that cause lymphadenopathy: Some chronic infectious diseases (HIV, Tuberculosis, Hepatitis B), Systemic diseases (rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, other rare systemic diseases*), Primary adrenal insufficiency (Addison´s disease), Leukemia, Lymphoma or other cancers (besides the type of cancer the participant is being examined for at the Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet)
  • Drugs that cause lymphadenopathy: Antibiotics (Cephalosporins, Penicillin, Sulfonamides), Antiepileptics (Carbamazepine, Ethosuximide, Lamotrigine, Phenytoin, Primidone), Antihypertensives (Atenolol, Captopril, Hydralazine), Other (Allopurinol, Imatinib)
  • Castleman's disease, Kikuchi's disease, Kawasaki disease, Inflammatory pseudotumor, Amyloidosis, Kimura disease, Rosai-Dorfman disease, IgG4-related disease, Still's disease, dermatomyositis, Churg-Strauss, histiocytosis, chronic granulomatous diseases, Autoimmune lymphoproliferative syndrome, lipid storage diseases.

Treatment and study plan

Malignant lymph nodes

Other

Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.

Primary outcomes

  1. Super-resolution ultrasound image of normal and malignant human lymph nodes

    Time frame: 1 minute

    With super-resolution ultrasound imaging, the investigators will visualize the microvasculature in the lymph nodes.

Secondary outcomes

  1. Vessel distribution

    Time frame: 1 minute

    Visual distribution of the nodal microvasculature

  2. Microvessel density

    Time frame: 1 minute

    The ratio of the vessel volume to the full volume in different regions

  3. Flow velocity

    Time frame: 1 minute

    In mm/s

  4. Vessel diameter

    Time frame: 1 min

    micrometer

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Technical University of Denmark
  • University of Copenhagen

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 6, 2023
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.